8-KLeadership ChangesRegulation FDOther Events+1

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Aug 22, 2013)

Filed August 22, 2013For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) filed an 8-K on August 22, 2013, detailing several significant corporate actions. Notably, the company announced the completion of a $450 million accelerated share repurchase (ASR) program and authorized a new, larger $1 billion stock repurchase program. A portion of the proceeds from a recent sale of ibrutinib royalty rights, approximately $300 million, will be allocated to this new repurchase initiative. These actions signal a commitment to returning capital to shareholders and managing its equity structure. Additionally, the company's Board of Directors plans to propose the elimination of supermajority voting requirements from its Certificate of Incorporation at the 2014 annual meeting, following a significant vote in favor of such a proposal by stockholders at the 2013 meeting. This move indicates a responsiveness to shareholder sentiment and a step towards aligning corporate governance with broader market practices.

Key Highlights

  • 1Completed a $450 million accelerated share repurchase (ASR) agreement.
  • 2Authorized a new $1 billion stock repurchase program.
  • 3Plans to use approximately $300 million from the sale of ibrutinib royalty rights for stock repurchases.
  • 4Board of Directors intends to recommend the elimination of supermajority voting requirements.
  • 5The decision to eliminate supermajority voting requirements follows a substantial shareholder vote in favor of the proposal at the 2013 annual meeting.
  • 6Mark J. Guinan has been designated as an executive officer and a Schedule B Participant in the Executive Officer Severance Plan.

Frequently Asked Questions

The completion of the $450 million ASR agreement demonstrates the company's active use of capital to reduce outstanding shares and potentially enhance shareholder value. It signifies the execution of a previously announced capital return strategy.

Quest Diagnostics has authorized a significant new stock repurchase program of $1 billion. This indicates a continued commitment to returning capital to shareholders. The company also plans to utilize approximately $300 million of the net proceeds from the recent sale of ibrutinib royalty rights for this repurchase program.

The Board of Directors will propose amendments to the Certificate of Incorporation to eliminate supermajority voting requirements at the 2014 annual meeting. This action is in response to a strong shareholder vote in favor of such a proposal at the 2013 meeting, suggesting a move towards more standard corporate governance practices and increased shareholder influence.

Mark J. Guinan is the Senior Vice President and Chief Financial Officer. He has been designated as an executive officer of the company and a participant in the Executive Officer Severance Plan, as updated.